A5039508054- COVID-19 Clinical Research Studies
- SARS-CoV-2 and COVID-19 Research
- COVID-19 Impact on Reproduction
- COVID-19 and healthcare impacts
- Long-Term Effects of COVID-19
- Pregnancy and Medication Impact
- Reproductive System and Pregnancy
- Vaccine Coverage and Hesitancy
- interferon and immune responses
National Institute of Genomic Medicine
2022-2023
Mexican Social Security Institute
2020-2023
Centro Medico Nacional Siglo XXI
2021-2023
Hospital de Especialidades
2021-2022
Current medical guidelines consider pregnant women with COVID-19 to be a high-risk group. Since physiological gestation downregulates the immunological response maintain “maternal-fetal tolerance”, SARS-CoV-2 infection may constitute potentially threatening condition both mother and fetus. To establish immune profile in COVID-19+ patients, cross-sectional study was conducted. Pregnant (P-COVID-19+; n = 15) were analyzed compared nonpregnant (NP-COVID-19+; or those pregnancy (P-COVID-19-;...
On January 30th, 2020, the WHO declared outbreak of COVID19, a disease due to new coronavirus called SARS-CoV-2. Certain comorbidities, symptoms and signs are characteristic COVID19 in general population pregnant women. However, women considered as high-risk group for COVID19. To know about frequency symptoms, presence lymphopenia, antibodies response SARS-CoV2 cytokine chemokine serum concentration, six with were studied at moment admission. The lower concentration CCL17 was detected...
The difficulty in predicting fatal outcomes patients with coronavirus disease 2019 (COVID-19) impacts the general morbidity and mortality due to severe acute respiratory syndrome-coronavirus 2 infection, as it wears out hospital services that care for these patients. Unfortunately, several of candidates prognostic biomarkers proposed, predictive power is compromised when have pre-existing comorbidities. A cohort 147 hospitalized COVID-19 was included a descriptive, observational,...
Abstract Current medical guidelines consider COVID-19 pregnant women a high-risk group. Physiological gestation down regulates the immunological response to maintain “maternal-fetal tolerance”; hence, SARS-CoV-2 infection constitutes potentially threatening condition both mother and fetus. To establish immune profile in COVID-19+ patients cross-sectional study was conducted. Leukocyte immunophenotype, mononuclear leukocyte polyclonal stimulus cytokine/chemokine serum concentration were...
Abstract Background The difficulty to predict fatal outcomes in COVID-19 patients, impacts the general morbidity and mortality due SARSCoV2 infection, as it wears out hospital services that care for these patients. Unfortunately, several of candidates prognostic biomarkers proposed, predictive power is compromised when patients have pre-existing co-morbidities. Methods A cohort one hundred forty-seven hospitalized severe COVID19 was included a descriptive, observational, single-center,...
Antecedentes: La vacunación es la intervención más efectiva para reducir carga de enfermedad por SARS-CoV-2; sin embargo, persisten brechas en el conocimiento relación con respuesta inmunológica los pacientes cáncer (PC). Objetivos: Evaluar humoral (anticuerpos anti-S) PC y trabajadores salud (TS) vacunados dos dosis vacuna BNT162b2 o AZD122. Material métodos: Se cuantificaron anticuerpos poliespecíficos contra proteína espiga SARS-CoV-2 (anti-S) se efectuó una puntuación propensión 1:1...
Vaccination is the most effective intervention for reducing burden of SARS-CoV-2-related disease; however, gaps in knowledge regarding cancer patients (CPs) immune response persist.To evaluate humoral (anti-S antibodies) CPs and healthcare workers (HCWs) vaccinated with two doses BNT162b2 or AZD122 vaccines.Polyspecific anti-SARS-CoV-2 spike protein (anti-S) antibodies were quantified, a 1:1 propensity score was used to balance baseline characteristics. Multiple logistic regressions carried...
Abstract Background Cancer patients (CPs) with COVID-19 have an increased risk of adverse outcomes. In addition, CPs seem to a lower immune response SARS-CoV-2 vaccination. This study aimed evaluate spike antibodies (anti-S Abs) following vaccination in and healthcare workers (HCWs). Methods We conducted point-seroprevalence HCWs who received two-dose scheme either BNT162b2, AZD1222, or Sputnik-V vaccine. measured anti-S Abs by quantitative immunoassay assess humoral response. Besides, we...